Tracking tech illuminates T cells for immuno-oncology research

Researchers at Tübingen University say they have developed a new tracking technology that will allow those working in the field of immuno-oncology to understand better how these new therapies are working.

Microbiome research opens a new pathway for autoimmune disease

The prospect that new research into the complex world of gut bacteria will deliver a whole new class of therapies has inspired the launch of a lineup of upstart biotechs. And now investigators in Belgium say they may have found a potentially compelling pathway for microbiome drug developers working in the autoimmune field.

Genetic error highlights a new approach to Fragile X syndrome

Investigators say that a single mutation in the gene linked to Fragile X--which is the largest single-gene cause of autism--can be tied to specific symptoms of the disease, suggesting that a new approach to treating the disease could work where others have failed.

Michigan investigators finger ATDC gene for aggressive pancreatic cancer

Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.

Microcapsules shuttle promising protein to treat osteoarthritis

Building on years of research into the anti-inflammatory and tissue-repairing properties of the protein molecule C-type natriuretic peptide, investigators in the U.K. say they have managed to overcome one of the hurdles that has prevented its use for treating osteoarthritis.

Alzheimer's investigators open a new front in BACE1 war

Scientists at the RIKEN-Max Planck Joint Research Center in Japan say that they may have found a new way to tackle BACE1, a prime target in Alzheimer's disease, while avoiding side effects.

Project identifies molecules for tumor suppression

Scientists from the Cancer Research UK Manchester Institute at The University of Manchester say they have been working on finding new molecules that play a role in tumor suppression.

Investigators electrify antibiotic R&D field with claims of a breakthrough

Antibiotic R&D fell out of favor at Big Pharma companies years ago, chilling a field that only recently has shown signs of heating up with new development projects. But a transatlantic team of investigators electrified the field this week with its claims that a new antibiotic found in dirt was a potent killer of drug-resistant bacteria. And it could represent a new class of badly needed antibiotics that just might avoid the natural resistance that begins to evolve once a new antibiotic hits the market.

Team takes a new approach to taming neuroinflammation

A team at Scripps is identifying enzymes that influence production of an inflammatory lipid molecule in the brain, offering a prime target for drug developers and insights that may also assist investigators in fields involving brain inflammation, such as multiple sclerosis, Alzheimer's, Parkinson's and ALS.

Amgen teams with MD Anderson on new BiTE programs for MDS

Fast on the heels of the FDA's approval of Blincyto (blinatumomab), Amgen's new leukemia fighter that uses a bispecific T cell engager system to flag cancer cells for the immune system to destroy, the Big Biotech has partnered up with MD Anderson in Texas on a new program aimed at identifying targets for this technology in myelodysplastic syndrome.

Scientists uncover new target for triple-negative breast cancer

About one of every 5 cases of breast cancer are termed triple-negative. They are hard to treat and resistant to some of the therapies currently in use, and as a result patients in this subtype have a worse chance of beating the disease or delaying its progress significantly. But now a team of scientists in the U.K. says that they have identified a gene that appears to drive disease progression and might offer a good target for drug developers.

Scripps researchers find a better way to make a nicotine vaccine

An attempt by Nabi to develop a new nicotine vaccine failed decisively in clinical studies, chilling the field for researchers who once dreamed of coming up with a better way to break a habit that can kill people through any of 8 different cancers. But now a team at Scripps Research Institute believe they've cracked the biologic code that defeated NicVAX and discovered how you could develop a vaccine that works.

Mouse study points to a particular T cell target for diabetes, insulin resistance

Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.

Cold Spring Harbor scientists find a biomarker for p53 cancer mutations

Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor.

Nanotech particles can exterminate as well as tag cancer cells for surgeons

Researchers at Oregon State University have adapted a known molecule so that it sticks to cancer cells, opening up a new approach to better identifying tumors for surgical removal while providing a follow-up attack on any remaining malignant cells, helping to prevent the cancer from making a comeback.

Positive primate study for Parkinson's inspires a rally for Minerva

Animal studies typically don't do much for a biotech's stock price. Findings can be hard to replicate, animal models often don't translate well to human studies and hopeful signs seen at the preclinical stage can vanish in an instant--particularly in tough fields like neurodegeneration.

Johns Hopkins stem cell team tests out CRISPR tech, with encouraging results

CRISPR technology's potential for gene editing has helped inspire the launch of a trio of closely watched biotech startups with their sights set on some cutting-edge approaches to new therapeutics. And now a team at Johns Hopkins has done some experiments to demonstrate its promise in engineering human stem cell therapies.

CHOP scientists herald new approach to neurodegenerative diseases

A team at Children's Hospital of Philadelphia says they've debunked a common misconception about the mTORC1 pathway and come up with a new and better approach that has proved promising in an animal model of Huntington's disease.

Stem cell researchers claim Harvard, Brigham mishandled probe

Two prominent researchers whose work on stem cells has come under review have fired back at Harvard Medical School and Brigham & Women's Hospital in a lawsuit, blaming a coauthor for the problems that triggered one paper to be retracted and another questioned while claiming that the university mishandled its investigation into their efforts.

Stem cell investigator resigns in wake of controversy

Stem cell investigator Haruko Obokata has resigned from Japan's RIKEN Center for Developmental Biology some months after a paper she co-authored on a new method to create pluripotent stem cells was retracted.